{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:36:27Z","timestamp":1792427787388,"version":"4.5.0"},"reference-count":12,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>We report a woman in her early 60s with right breast carcinoma who received chemotherapy, whole breast radiotherapy and pembrolizumab (immune checkpoint inhibitor). During the sixth pembrolizumab cycle, she developed progressive cough and exertional dyspnoea. CT of the thorax revealed a right upper lobe consolidation with air bronchogram and surrounding ground-glass opacities, while bronchoalveolar lavage excluded infection and malignancy. A diagnosis of overlapping radiation-induced and pembrolizumab-induced pneumonitis was made. Oral corticosteroids led to rapid clinical improvement, with radiological resolution and spirometry improvement within 3\u2009months. This case illustrates the diagnostic challenge of differentiating immune-related from radiation-induced pneumonitis, particularly when therapies are administered sequentially. It also emphasises the importance of careful evaluation and timing of pembrolizumab initiation after radiotherapy to mitigate pneumonitis risk. Systematic exclusion of alternative causes, awareness of dual pathology and prompt corticosteroid therapy remain critical to ensure favourable outcomes in patients undergoing multimodal cancer treatment.<\/jats:p>","DOI":"10.1136\/bcr-2025-269851","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:00:34Z","timestamp":1768590034000},"page":"e269851","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Sequential radiation-induced and immune checkpoint inhibitor-induced pneumonitis in a patient with breast carcinoma"],"prefix":"10.1136","volume":"19","author":[{"given":"Mohamed Faisal","family":"Abdul Hamid","sequence":"first","affiliation":[{"name":"Universiti Kebangsaan Malaysia Fakulti Perubatan, Cheras, Federal Territory of Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1721-6329","authenticated-orcid":false,"given":"Mohd Jazman","family":"Che Rahim","sequence":"additional","affiliation":[{"name":"Medical, Hospital Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia"},{"name":"Universiti Sains Malaysia - Kampus Kesihatan, Kota Bharu, Kelantan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrah","family":"Arif","sequence":"additional","affiliation":[{"name":"Universiti Kebangsaan Malaysia Fakulti Perubatan, Cheras, Federal Territory of Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mas Fazlin","family":"Mohamad Jailaini","sequence":"additional","affiliation":[{"name":"Universiti Kebangsaan Malaysia Fakulti Perubatan, Cheras, Federal Territory of Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026011611001534000_19.1.e269851.1","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"2026011611001534000_19.1.e269851.2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026011611001534000_19.1.e269851.3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00066-022-02032-y","article-title":"Systematic risk analysis of radiation pneumonitis in breast cancer: role of cotreatment with chemo-, endocrine, and targeted therapy","volume":"199","author":"Mangesius","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"2026011611001534000_19.1.e269851.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00071303"},{"key":"2026011611001534000_19.1.e269851.5","first-page":"37","article-title":"Radiation-induced lung injury. Assessment, management, and prevention","volume":"22","author":"Ghafoori","year":"2008","journal-title":"Oncology (Williston Park)"},{"key":"2026011611001534000_19.1.e269851.6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12254-021-00756-8","article-title":"Checkpoint inhibitor pneumonitis: Short review of literature and case report","volume":"15","author":"Wass","year":"2022","journal-title":"memo"},{"key":"2026011611001534000_19.1.e269851.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"2026011611001534000_19.1.e269851.8","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026011611001534000_19.1.e269851.9","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.718093"},{"key":"2026011611001534000_19.1.e269851.10","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0058-2019","article-title":"Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer","volume":"28","author":"Cadranel","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2026011611001534000_19.1.e269851.11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.918787","article-title":"Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer","volume":"13","author":"Lu","year":"2022","journal-title":"Front Immunol"},{"key":"2026011611001534000_19.1.e269851.12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","article-title":"Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database","volume":"8","author":"Anscher","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-269851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:00:35Z","timestamp":1768590035000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-269851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bcr-2025-269851"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-269851","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}